间充质干细胞治疗脊髓损伤的可视化分析

doi:10.3969/j.issn.1006-9771.2020.04.006

摘要/Abstract

摘要：

目的分析近5年间充质干细胞(MSCs)治疗脊髓损伤的研究现状和热点。方法检索2014年至2018年Web of Science中SCI-E收录的相关文献,采用CiteSpace软件分析作者、国家/机构的合作关系,对关键词进行共现分析、聚类分析、动态前沿演化及burst分析,对期刊、文献的共被引情况进行分析,绘制可视化图谱并分析结果。结果与结论 共纳入作者236位,其中49位作者发文量≥ 3篇,高产作者主要以Zeng Y S和Chen L为代表。共纳入国家/机构162个,其中85个国家/机构发文量≥ 3篇;共纳入期刊75个,Exp Neurol是收录文章最多的期刊;共纳入关键词107个,热点关键词为脊髓损伤、MSCs、移植、骨髓、修复、功能恢复,可形成6个聚类群。预测发展趋势为提取培养祖细胞,并诱导其定向分化;MSCs治疗脊髓损伤的免疫调节、抗炎、神经再生作用机制研究,以及组织工程技术,生物材料在该领域的研究。

关键词: 脊髓损伤, 间充质干细胞, CiteSpace, Web of Science, 可视化分析

Abstract:

Objective To analyze the research status and hotspots of mesenchymal stem cells (MSCs) for treatment of spinal cord injury in the past five years.Methods The related literatures from 2014 to 2018 in Science Citation Index-Expanded (SCI-E) of Web of Science (WOS) were included. CiteSpace software was used to analyze the cooperation relationship of authors, countries and research institutions. The keywords were taken as nodes for co-occurrence analysis, cluster analysis, dynamic frontier evolution and burst analysis. The co-citation of journals and literatures were taken as nodes for analysis, meanwhile, the visual maps were drawn and the results were analyzed.Results and Conclusion A total of 236 authors were included, out of whom 49 authors published more than three papers, and high-yielding authors were mainly represented by Zeng Y S and Chen L. There were 162 countries/institutions involved, out of which 85 published more than three papers. Seventy-five journals were included, out of which Exp Neurol was the one with the most articles. There were 107 key words included, and the hot words were spinal cord injury, MSCs, transplantation, bone marrow, repair, and functional recovery, which formed six cluster groups. The trend was to extract and culture progenitor cells and induce their directional differentiation; mechanism of immune regulation, anti-inflammatory and nerve regeneration in the treatment of spinal cord injury by MSCs, as well as the research of tissue engineering technology, biological materials in this field.

Key words: spinal cord injury, mesenchymal stem cells, CiteSpace, Web of Science, visual analysis

中图分类号:

R651.2

叶佳美,胡晓敏,王丽群,王文春,张安仁. 间充质干细胞治疗脊髓损伤的可视化分析[J]. 《中国康复理论与实践》, 2020, 26(4): 400-406.

YE Jia-mei,HU Xiao-min,WANG Li-qun,WANG Wen-chun,ZHANG An-ren. Researches on Mesenchymal Stem Cells for Treatment of Spinal Cord Injury: A Visualization Analysis[J]. 《Chinese Journal of Rehabilitation Theory and Practice》, 2020, 26(4): 400-406.

图/表 12

图1

图2

图3

图4

图5

表1

表2

图6

图7

表3

图8

图9

参考文献 37

[1]	Nagoshi N, Okano H. Applications of induced pluripotent stem cell technologies in spinal cord injury[J]. J Neurochem, 2017, 141(6):848-860. doi: 10.1111/jnc.2017.141.issue-6
[2]	Caplan A I. Why are MSCs therapeutic? New data: new insight[J]. J Pathol, 2009, 217(2):318-324. doi: 10.1002/path.v217:2
[3]	Sart S, Tsai A C, Li Y, et al. Three-dimensional aggregates of mesenchymal stem cells: cellular mechanisms, biological properties, and applications[J]. Tissue Eng Part B Rev, 2014, 20(5):365-380. doi: 10.1089/ten.teb.2013.0537
[4]	De Miguel M P, Fuentes-Julian S, Blazquez-Martinez A, et al. Immunosuppressive properties of mesenchymal stem cells: advances and applications[J]. Curr Mol Med, 2012, 12(5):574-591. pmid: 22515979
[5]	陈悦, 刘则渊, 陈劲, 等. 科学知识图谱的发展历程[J]. 科学学研究, 2008, 26(3):449-460.
[6]	陈悦, 陈超美, 刘则渊, 等. CiteSpace知识图谱的方法论功能[J]. 科学学研究, 2015, 33(2):242-253.
[7]	Qiu X C, Jin H, Zhang R Y, et al. Donor mesenchymal stem cell-derived neural-like cells transdifferentiate into myelin-forming cells and promote axon regeneration in rat spinal cord transaction[J]. Stem Cell Res Ther, 2015, 6(1):105. doi: 10.1186/s13287-015-0100-7
[8]	Li G, Che M T, Zhang K, et al. Graft of the NT-3 persistent delivery gelatin sponge scaffold promotes axon regeneration, attenuates inflammation, and induces cell migration in rat and canine with spinal cord injury[J]. Biomaterials, 2016, 83(8):233-248. doi: 10.1016/j.biomaterials.2015.11.059
[9]	Zeng X, Qiu X C, Ma Y H, et al. Integration of donor mesenchymal stem cell-derived neuron-like cells into host neural network after rat spinal cord transaction[J]. Biomaterials, 2015, 53:184-201. doi: 10.1016/j.biomaterials.2015.02.073
[10]	Chen L, Huang H, Xi H, et al. A prospective randomized double-blind clinical trial using a combination of olfactory ensheathing cells and Schwann cells for the treatment of chronic complete spinal cord injuries[J]. Cell Transplant, 2014, 23(1):35-44.
[11]	Chen L, Cui X, Wu Z, et al. Transplantation of bone marrow mesenchymal stem cells pretreated with valproic acid in rats with an acute spinal cord injury[J]. Biosci Trends, 2014, 8(2):111-119. pmid: 24815388
[12]	Peng Z, Gao W, Yue B, et al. Promotion of neurological recovery in rat spinal cord injury by mesenchymal stem cells loaded on nerve-guided collagen scaffold through increasing alternatively activated macrophage polarization[J]. J Tissue Eng Regen Med, 2018, 12(3):e1725-e1736.
[13]	Yuan X, Wu Q, Wang P, et al. Exosomes derived from pericytes improve microcirculation and protect blood-spinal cord barrier after spinal cord injury in mice[J]. Front Neurosci, 2019, 13:319. doi: 10.3389/fnins.2019.00319
[14]	Hua R, Li P, Wang X, et al. Evaluation of somatosensory evoked potential and pain rating index in a patient with spinal cord injury accepted cell therapy[J]. Pain Physician, 2016, 19(4):E659-E666.
[15]	Tetzlaff W, Okon E B, Karimi-Abdolrezaee S, et al. A systematic review of cellular transplantation therapies for spinal cord injury[J]. J Neurotrauma, 2011, 28(8):1611-1682. doi: 10.1089/neu.2009.1177
[16]	Osaka M, Honmou O, Murakami T, et al. Intravenous administration of mesenchymal stem cells derived from bone marrow after contusive spinal cord injury improves functional outcome[J]. Brain Res, 2010, 1343:226-235. doi: 10.1016/j.brainres.2010.05.011
[17]	Ryu H H, Lim J H, Byeon Y E, et al. Functional recovery and neural differentiation after transplantation of allogenic adipose-derived stem cells in a canine model of acute spinal cord injury[J]. J Vet Sci, 2009, 10(4):273-284. doi: 10.4142/jvs.2009.10.4.273
[18]	Nakajima H, Uchida K, Guerrero A R, et al. Transplantation of mesenchymal stem cells promotes an alternative pathway of macrophage activation and functional recovery after spinal cord injury[J]. J Neurotrauma, 2012, 29(8):1614-1625. doi: 10.1089/neu.2011.2109
[19]	Park J H, Kim D Y, Sung I Y, et al. Long-term results of spinal cord injury therapy using mesenchymal stem cells derived from bone marrow in humans[J]. Neurosurgery, 2012, 70(5):1238-1247. doi: 10.1227/NEU.0b013e31824387f9
[20]	Sasaki M, Radtke C, Tan A M, et al. BDNF-hypersecreting human mesenchymal stem cells promote functional recovery, axonal sprouting, and protection of corticospinal neurons after spinal cord injury[J]. J Neurosci, 2009, 29(47):14932-14941. doi: 10.1523/JNEUROSCI.2769-09.2009
[21]	Quertainmont R, Cantinieaux D, Botman O, et al. Mesenchymal stem cell graft improves recovery after spinal cord injury in adult rats through neurotrophic and pro-angiogenic actions[J]. PLoS One, 2012, 7(6):e39500. doi: 10.1371/journal.pone.0039500
[22]	Wright K T, El Masri W, Osman A, et al. Concise review: Bone marrow for the treatment of spinal cord injury: mechanisms and clinical applications[J]. Stem Cells, 2011, 29(2):169-178. doi: 10.1002/stem.v29.2
[23]	Onose G, Anghelescu A, Muresanu D F, et al. A review of published reports on neuroprotection in spinal cord injury[J]. Spinal Cord, 2009, 47(10):716-726. doi: 10.1038/sc.2009.52 pmid: 19597522
[24]	Kwon B K, Okon E, Hillyer J, et al. A systematic review of non-invasive pharmacologic neuroprotective treatments for acute spinal cord injury[J]. J Neurotrauma, 2011, 28(8):1545-1588. doi: 10.1089/neu.2009.1149
[25]	Silva N A, Sousa N, Reis R L, et al. From basics to clinical: a comprehensive review on spinal cord injury[J]. Prog Neurobiol, 2014, 114:25-57. doi: 10.1016/j.pneurobio.2013.11.002 pmid: 24269804
[26]	Sart S, Tsai A C, Li Y, et al. Three-dimensional aggregates of mesenchymal stem cells: cellular mechanisms, biological properties, and applications[J]. Tissue Eng Part B Rev, 2014, 20(5):365-380. doi: 10.1089/ten.teb.2013.0537
[27]	Adami R, Scesa G, Bottai D. Stem cell transplantation in neurological diseases: improving effectiveness in animal models[J]. Front Cell Dev Biol, 2014, 2:17.
[28]	Friedenstein A J, Petrakova K V, Kurolesova A I, et al. Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues[J]. Transplantation, 1968, 6(2):230-247. pmid: 5654088
[29]	Karamouzian S, Nematollahi-Mahani S N, Nakhaee N, et al. Clinical safety and primary efficacy of bone marrow mesenchymal cell transplantation in subacute spinal cord injured patients[J]. Clin Neurol Neurosurg, 2012, 114(7):935-939. doi: 10.1016/j.clineuro.2012.02.003
[30]	Geffner L F, Santacruz P, Izurieta M, et al. Administration of autologous bone marrow stem cells into spinal cord injury patients via multiple routes is safe and improves their quality of life: comprehensive case studies[J]. Cell Transplant, 2008, 17(12):1277-1293. pmid: 19364066
[31]	Kumar A A, Kumar S R, Narayanan R, et al. Autologous bone marrow derived mononuclear cell therapy for spinal cord injury: a phase I/II clinical safety and primary efficacy data[J]. Exp Clin Transplant, 2009, 7(4):241-248.
[32]	赵建保. CiteSpace可视化流程与分析范式研究[J]. 知识经济, 2014(16):105-107.
[33]	Geissler S A, Sabin A L, Besser R R, et al. Biomimetic hydrogels direct spinal progenitor cell differentiation and promote functional recovery after spinal cord injury[J]. J Neural Eng, 2018, 15(2):25004. doi: 10.1088/1741-2552/aaa55c pmid: 29303112
[34]	Yi T, Song S U. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications[J]. Arch Pharm Res, 2012, 35(2):213-221. doi: 10.1007/s12272-012-0202-z
[35]	Duffy M M, Ritter T, Ceredig R, et al. Mesenchymal stem cell effects on T-cell effector pathways[J]. Stem Cell Res Ther, 2011, 2(4):34. doi: 10.1186/scrt75
[36]	Fierabracci A, Del F A, Luciano R, et al. Recent advances in mesenchymal stem cell immunomodulation: the role of microvesicles[J]. Cell Transplant, 2015, 24(2):133-149. doi: 10.3727/096368913X675728 pmid: 24268069
[37]	Bonab M M, Sahraian M A, Aghsaie A, et al. Autologous mesenchymal stem cell therapy in progressive multiple sclerosis: an open label study[J]. Curr Stem Cell Res Ther, 2012, 7(6):407-414. doi: 10.2174/157488812804484648

聚类ID	包含关键词
2	条件培养基、组织工程、创伤性脑损伤、支架、神经再生、干细胞/祖细胞、功能恢复、神经元、神经变性疾病等
3	损伤、骨髓基质细胞、施万细胞、轴突再生、呼吸黏膜间充质干细胞、脊髓损伤、神经蛋白聚糖、神经元分化、感觉轴突、突触可塑性等
4	神经修复、转化神经科学、细胞再生疗法、骨骼肌再生、运动恢复、细胞疗法、临床神经修复、完全性慢性脊髓损伤等
5	创伤性脑损伤、神经保护、脊髓损伤、神经干细胞、视网膜神经节细胞、介导免疫抑制、分化能力、分泌因子、趋化因子受体等